B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patientsArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval Affect anti-CD20 anti-CD20 treatment antibody Antibody Response Antibody titers B cell B cells B-cell B-cell depletion Blood booster cellular response Cohort correlated detectable develop Efficacy Guidance humoral identify IgG^{+} interleukin-13 Logistic regression median memory multiple sclerosis naïve no correlation Odds ratio Patient patients predict predictor Probability recent rituximab S1 domain SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Seroconversion T-cell Response treated Treatment turn vaccination vaccine responses [DOI] 10.1111/ene.15492 PMC 바로가기
Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune diseaseArticle Published on 2022-09-142022-11-15 Journal: BMC Infectious Diseases [Category] SARS, 진단, [키워드] Adequate anti-CD20 anti-CD20 treatment antibody antibody treatment Autoimmune disease B-cell B-cells CD19 CD20 cellular cellular response clinical correlated COVID-19 depleting develop disease generate humoral immune Immunity immunization kidney modulating Patient patients receiving treatment receiving regimens Registered renal response retrospective rituximab SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine single-center timespan Treatment vaccination vaccination response [DOI] 10.1186/s12879-022-07722-7 PMC 바로가기
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort StudyCOVID-19 백신 접종 후 항-CD20 치료 환자의 강력한 T-세포 반응: 전향적 코호트 연구Observational Study Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus anti-CD20 anti-CD20 therapy anti-CD20 treatment antibodies antibody Antibody Response Arthritis Breakthrough infection CD20 CD4 CD4 T cell CD8 T cell CD8 T cells cohort study Complication Control controls coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine detectable dose Effectiveness effector molecule effector molecules expressed Follow-up had no humoral humoral responses individual Mild mRNA COVID-19 vaccines mRNA-based COVID-19 vaccine multiple sclerosis Ocrelizumab Patient patients treated Prospective prospective observational cohort reduction respiratory response response rate response rates rheumatic disease Rheumatic diseases rheumatoid arthritis risk rituximab seroconverted severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe coronavirus disease severe COVID-19 significantly lower specific antibodies spike T cell T cells T-cell T-cell Response T-cell responses Th1 phenotype treated treated patient vaccination [DOI] 10.1093/cid/ciab954 PMC 바로가기 [Article Type] Observational Study
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses증례 보고: 백신 접종 반응이 없는 다발성 경화증 환자에서 SARS-CoV-2 감염의 변종 특이적 노출 전 예방Case Reports Published on 2022-07-252022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-CD20 treatment antibody cocktail approved Asymptomatic Case report Case series case sery Casirivimab cilgavimab conducted coronavirus coronavirus disease coronavirus disease (COVID-19) COVID-19 infection develop dose European Evidence evidence of FIVE humoral Imdevimab immunomodulatory Immunotherapy impair incidence Infection Initially monoclonal monoclonal antibody multiple sclerosis Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody offered omicron Omicron variant one patient pandemic Patient patients positive RT-PCR predominant prophylactic treatment Prophylaxis receptor reduced respiratory respiratory tract infection response retained Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic SARS-CoV-2-neutralizing antibodies SARS-CoV-2-neutralizing antibody SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severe adverse event severe adverse events Sotrovimab specific antibodies sphingosine sphingosine-1-phosphate sphingosine-1-receptor modulators (S1PR) sustained Symptom T-cell T-cells the patient the SARS-CoV-2 Tixagevimab Treatment union upper respiratory tract upper respiratory tract infection vaccination vaccination response variant were recorded [DOI] 10.3389/fimmu.2022.897748 PMC 바로가기 [Article Type] Case Reports
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis질병 조절 요법 후 다발성 경화증 환자에서 COVID-19 예방 접종의 반응: 메타 분석Meta-Analysis Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 바이오마커, 유전자 메커니즘, [키워드] addressed anti-CD20 anti-CD20 therapy anti-CD20 treatment association benefit booster dose CD20 cellular response Cochrane Library conducted COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Disease-modifying therapies Efficacy evaluate foundation humoral Humoral response IFN-β immune response literature medRxiv Meta-analysis Multiple multiple sclerosis natural no significant difference Odds ratio Odds ratios other treatment other treatments Patient random-effect receiving receptor required response response to vaccination risk SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines Science Serologic response serological Shanghai significantly higher sphingosine sphingosine-1-phosphate suggested supported T-cell Response therapy Treatment vaccination was performed [DOI] 10.1016/j.ebiom.2022.104102 PMC 바로가기 [Article Type] Meta-Analysis
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19난치성 COVID-19를 가진 항-CD20 치료를 받는 여성의 중화 항체를 강화하기 위한 카시리비맙/임데비맙 항-스파이크 단일클론 항체의 성공적인 사용Article Published on 2022-07-012022-09-12 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 변종, 진단, 치료법, [키워드] anti-CD20 Anti-CD20 monoclonal antibody anti-CD20 treatment anti-spike monoclonal antibody casirivimab/imdevimab COVID-19 COVID-19 patient ENhance humoral immunodeficiency monoclonal monoclonal antibody monoclonal antibody treatment Neutralizing antibodies neutralizing antibody neutralizing monoclonal antibody Patient Prophylactic Relapse rituximab therapeutic treated with COVID-19 [DOI] 10.1016/j.jiac.2022.03.002 PMC 바로가기 [Article Type] Article
Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies질병 변형 요법으로 치료받는 다발성 경화증 환자에서 일반적인 3회 투여 일정에 따른 SARS-CoV-2 백신 접종에 대한 항체 반응Article Published on 2022-07-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age anti-CD20 anti-CD20 treatment antibody benefit COVID-19 disease Disease modifying treatment dose dosing schedule fumarate humoral immune system immunization Immunocompromised interferon medication mRNA vaccination MS multiple sclerosis Part Patient patients patients treated retrospective SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 virus spike tested the vaccine therapy treated treated patients treatment with anti-CD20 vaccination Vaccine vaccine response [DOI] 10.1016/j.msard.2022.103856 PMC 바로가기 [Article Type] Article
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple SclerosisResearch article Published on 2022-07-012022-10-05 Journal: Multiple sclerosis and related disorders [Category] 유전자 메커니즘, [키워드] age analyses anti-CD20 treatment applied approach AUC Bayesian BMI calculate calculated can be used Characteristics Clinical practice coefficient country Course COVID-19 severity cut-off dataset defined disability disease EDSS equipment evaluate external validation form General population high-risk patient higher risk Hospitalization identify Infection Italy LASSO linear combination logistic regression model Male sex measure Methylprednisolone missing values Multiple multiple sclerosis multivariable multivariable logistic regression Older age Patient patients performed platform Predictive presence of comorbidities Prevent Probability required Result risk Risk assessment score risk factor ROC Curve scale sclerosis separated severity Sex social distancing South America status the patient training data training dataset Treatment Turkey variable [DOI] 10.1016/j.msard.2022.103909 [Article Type] Research article
Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis다발성 경화증 환자의 항-COVID19 백신 접종에 대한 항체 매개 반응에 대한 질병 조절 치료의 효과Article Published on 2022-06-012022-09-11 Journal: Journal of Neurology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Adverse adverse event adverse events age aligned analysed anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD20 treatment Anti-spike antibody Antibody Response CD19 CD19+ CD20 CD20 deplething therapies cell count cell-mediated immune cell-mediated immune response Cohort correlated COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccines depleting detectable diagnosed Disease-modifying therapies Effect elicited event female fingolimod Follow-up Frequency IgG antibody immune response investigation material median median age Multiple multiple sclerosis non-responders Patient proportion protective immune response Protein receiving recorded Responder responders symptomatic therapy titre treated Treatment vaccination Vaccine was reduced [DOI] 10.1007/s00415-022-11003-3 PMC 바로가기 [Article Type] Article
Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series코로나바이러스 질병 2019 환자의 렘데시비르 항-CD20 단일클론항체 치료: 사례 시리즈Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: Infection [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료제, [키워드] administration anti-CD20 Anti-CD20 antibodies anti-CD20 treatment antiviral therapy approved baseline baseline data benefit Case series case sery Clinical improvement Clinical outcome consecutive patient control group convalescent plasma COVID-19 COVID-19 patient COVID-19 symptoms Diagnosis died disease course Follow-up healthcare Infection lack majority malignancy management median monoclonal not performed one patient outcomes pandemic Patient patient population patients patients died patients treated PCR performed Randomized controlled trial Randomized controlled trials reductions reductions in relapsing Remdesivir reported rituximab SARS-CoV-2 Study design symptom onset Symptoms These data Treatment two patients Viral viral clearance viral loads [DOI] 10.1007/s15010-022-01821-y PMC 바로가기 [Article Type] Randomized Controlled Trial